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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.003Cancer cells condition macrophages and other inﬂammatory cells in the tumor microenvironment so that
these cells are more permissive for cancer growth and metastasis. Conditioning of inﬂammatory cells reﬂects,
at least in part, soluble mediators (such as transforming growth factor b and IL-4) that are released by cancer
cells and alter the phenotype of cells of the innate immune system. Signaling pathways in cancer cells that
potentiate this activity are incompletely understood. The urokinase receptor (uPAR) is a cell-signaling re-
ceptor known to promote cancer cell survival, proliferation, metastasis, and cancer stem cellelike properties.
The present ﬁndings show that uPAR expression in diverse cancer cells, including breast cancer, pancreatic
cancer, and glioblastoma cells, promotes the ability of these cells to condition co-cultured bone marrowe
derived macrophages so that the macrophages express signiﬁcantly increased levels of arginase 1, a
biomarker of the alternatively activated M2 macrophage phenotype. Expression of transforming growth
factor b was substantially increased in uPAR-expressing cancer cells via a mechanism that requires uPA-
initiated cell signaling. uPAR also controlled expression of IL-4 in cancer cells via a mechanism that involves
activation of ERK1/2. The ability of uPAR to induce expression of factors that condition macrophages in the
tumor microenvironment may constitute an important mechanism by which uPAR promotes cancer pro-
gression. (Am J Pathol 2014, 184: 3384e3393; http://dx.doi.org/10.1016/j.ajpath.2014.08.003)Supported by NIH grant R01-CA169096 (S.L.G.).
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disclosures relative to her new afﬁliation with Isis Pharmaceuticals.
Current address of M.J., Isis Pharmaceuticals, Carlsbad, CA.It is well established that certain chronic infections and
inﬂammation predispose to the development ofmalignancy.1e3
Once cancer develops, inﬂammatory cells that inﬁltrate the
tumor may promote disease progression.4e6 This process is
mediated by bidirectional paracrine pathways involving cancer
and inﬂammatory cells. Growth factors and cytokines released
by cancer cells are immunosuppressive, and also condition
inﬂammatory cells so that these cells release mediators
that support cancer cell growth, survival, metastasis, and
angiogenesis.7e10 Inﬂammatory cell conditioning is prevalent
in breast cancer. These tumors include large numbers of mac-
rophages, dendritic cells, mast cells, and T cells, and the extent
to which the tumor is inﬁltrated by these inﬂammatory cells
correlates with the incidence of metastasis.11e13 A high density
of tumor-associated macrophages (TAMs) is also correlated
with higher breast cancer tumor grade and decreased relapse-
free and overall survival.14e17
Although macrophages express a wide spectrum of pheno-
typic properties, these cells are frequently categorized asstigative Pathology.
.classically activated (M1) or alternatively activated (M2).18e21
In response to pathogens, tissue damage, and Th1 cytokines
such as IFN-g and TNF-a, M1-polarized macrophages release
cytotoxic compounds and proteins, including nitric oxide,
reactive oxygen species, and proinﬂammatory cytokines
(including IL-12, IL-23, and TNF-a). M2-polarized macro-
phage have been classiﬁed into a number of subcategories;
in many contexts, these cells demonstrate enhanced activity
in the resolution of inﬂammation, tissue remodeling, and
healing.18e21 Arginase 1 (Arg1), which is expressed selectively
by M2-polarized macrophages, diverts substrate from the
enzyme systems that produce cytotoxic levels of nitric
oxide.22,23 In general, it is thought that TAMs, which have been
Cancer Cell Conditioning of Macrophagesconditioned by cancer cells to express tumor-permissive gene
products, demonstrate characteristics in common with M2-
polarized macrophages, although a recent report highlights
phenotypic differences.18,19,24 Cell-signaling systems in tumor
cells that promote the ability of these cells to regulate macro-
phage phenotype remain incompletely understood.
In many forms of cancer, expression of the urokinase
receptor [urokinase plasminogen activator receptor (uPAR)]
correlates with poor prognosis and shortened survival.25e28
Originally, the activity of uPAR in cancer was attributed to
its ability to bind the serine protease, urokinase-type plas-
minogen activator (uPA), and activate a cascade of extracel-
lular proteases involved in matrix remodeling and cell
migration through tissue boundaries. The current understand-
ing, however, is that uPAR also is a cell-signaling receptor that
activates diverse signaling pathways.29 Although uPAR may
signal autonomously when expressed at high levels, uPA
binding to uPAR robustly activates cell signaling even when
the cell-surface abundance of uPAR is low.29e32 uPAR-
initiated cell signaling promotes cancer cell survival, release
from states of dormancy, migration, epithelialemesenchymal
transition, cancer stem cellelike properties, and metastasis
independently of protease activation.33e38
Here, we show that in multiple forms of cancer, including
breast cancer, pancreatic cancer, and glioblastoma (GBM),
uPAR expression promotes the ability of the cancer cells to
M2-polarize co-cultured macrophages. The mediators that are
released selectively by uPAR-expressing cancer cells to
regulate macrophage phenotype may vary across different
cancer cells; however, we provide evidence that both TGF-b
and IL-4 are involved. The ability of cancer-cell uPAR to
promote conditioning of inﬂammatory cells in the tumor
microenvironment is a novel mechanism by which uPARmay
promote cancer progression.
Materials and Methods
Reagents
AntieF4/80 (phycoerythrin PE conjugated) and isotype-
matched IgG were from eBioscience (San Diego, CA).
Monoclonal human uPAR-speciﬁc antibody (ATN658) for
ﬂow cytometry was provided by Dr. Andrew Mazar (North-
western University). Rabbit monoclonal antibody that detects
both TGF-b1 and TGF-b3 (56E4) was from Cell Signaling
Technology (Danvers, MA).Monoclonal antibody that detects
a-tubulin was from Sigma-Aldrich (St. Louis, MO). Mouse
uPAR-speciﬁc antibody for ﬂow cytometry was from R&D
Systems (Minneapolis, MN). The MAP kinase (MEK) inhib-
itor PD98059 was from Calbiochem (San Diego, CA). qPCR
reagents, including primers and probes for mouse Arg1, uPA,
TGF-b, IL-4, and HPRT-1 were from Applied Bio-
systemseLife Technologies (Carlsbad, CA). The TGF-b
primers and probe were selective for TGF-b1. The siRNA
targeting human uPA is previously described.39 An siCON-
TROL nontargeting siRNA pool [non-targeting controlThe American Journal of Pathology - ajp.amjpathol.org(NTC)] was obtained from Dharmacon (GE Dharmacon,
Lafayette, CO).
Cell Culture
MDA-MB 468 breast cancer cells were obtained from the
ATCC (Manassas, VA). Low-passage MCF7 cells were
originally provided by Dr. Sally Parsons (University of Vir-
ginia, Charlottesville, VA). Stable derivative cell lines were
used in which MDA-MB 468 and MCF7 cells were trans-
fected to overexpress human uPARorwith empty vector (EV),
as described previously.32,36,38 Expression of uPAR was
conﬁrmed by ﬂow cytometry (FACSCanto II system; BD
Biosciences, San Jose, CA) and the results were analyzed
using FlowJo software version 7.6.4 (TreeStar, Ashland, OR).
MCF-7 and MDA-MB 468 cells were maintained in Dulbec-
co’s modiﬁed Eagle’s medium supplemented with 10% fetal
bovine serum. siRNA (40 nmol/L) was introduced into control
and uPAR-overexpressing MDA-MB 468 cells by incubation
with Lipofectamine 2000 transfection reagent (Life Technol-
ogies) according to the manufacturer’s instructions. 4T1 and
168FARNmousemammary cancer cells (generously provided
by Dr. Fred R. Miller, Wayne State University, Detroit, MI)
were maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum. PanO2 mouse
pancreatic adenocarcinoma cells were obtained from the Na-
tional Cancer Institute Developmental Therapeutics Program
Tumor Repository and cultured as described previously.40
These cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium with 10% fetal bovine serum. uPAR was silenced in
PanO2 and 4T1 cells by transducing these cells with a lenti-
virus that encodes shRNA targeting mouse uPAR (pLKO-
shmuPAR; RNAi Consortium, Broad Institute, Cambridge,
MA). The sequence 50-ACCAACAGGACCATG-30 in the
shRNA corresponds to nucleotides 231 to 246 in the coding
region of mouse uPAR. Control cells were transduced with
viral particles that contain EV. Transduced cells were selected
with 2 mg/mL puromycin for 1 week. uPAR protein expression
was then assessed by ﬂow cytometry or immunoblot analysis.
ESC1 and ESC2 (Ludwig Institute for Cancer Research,
University of California, San Diego) are GBM cell lines
established by harvesting two separate xenografts formed by
U373MG GBM cells.41 These cells, which are known to
express high levels of uPA and uPAR, were cultured as
described previously.39
Co-Culturing Experiments with BMDMs
Bone marrowederived macrophages (BMDMs) were har-
vested from femurs and tibias of 8- to 10-week-old female
C57BL/6 mice (Charles River Laboratories, San Diego,
CA) and cultured in Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal bovine serum and 20% L929
celleconditioned medium for 7 days.40,42 The BMDMs
were released with trypsin. The purity of BMDMs was
conﬁrmed by performing ﬂow cytometry for the macrophage3385
Figure 1 Urokinase receptor (uPAR) overexpression in MDA-MB 468
breast cancer cells increases arginase 1 (Arg1) expression in co-cultured
bone marrowederived macrophages (BMDMs). A: Flow cytometry was per-
formed to detect uPAR in MCF7 and MDA-MB 468 cells. uPAR-overexpressing
cells (gray curve); empty vector (EV)etransfected control cells (black
curve); and isotype-matched IgG (dotted curve). B: BMDM Arg1 mRNA was
analyzed by quantitative real-time PCR (qPCR) after co-culturing with
control cancer cells, transfected with EV, or with cells transfected to
overexpress human uPAR (uPAR). C: After co-culturing with cancer cells,
BMDM arginase activity was assessed as the arginase activity index, an
indicator of the amount of urea produced by BMDMs. Data are expressed as
means  SEM. n Z 3, with internal duplicate replicates. *P < 0.05;
***P < 0.001, one-way analysis of variance. Max, maximum; no cells, no
cancer cells were added to the co-culture inserts.
Figure 2 Urokinase receptor (uPAR) controls the ability of 4T1 meta-
static breast cancer cells to regulate expression of arginase 1 (Arg 1) in co-
cultured bone marrow-derived macrophages (BMDMs). A: Flow cytometry
was performed to detect mouse uPAR in 168FARN (black curve) and 4T1
(gray curve) cells and in isotype-matched IgG (dotted curve). B: Flow
cytometry was performed to detect mouse uPAR in 4T1 cells transduced
with a control lentiviral vector, 4T1-shCon cells (gray curve), or with a
lentiviral vector encoding shRNA against uPAR, 4T1-shuPAR cells (black
curve). An isotype-matched IgG control study is also shown (dotted curve).
C and D: After co-culturing with cancer cells, BMDM Arg1 mRNA was
analyzed by qPCR (C) and BMDM arginase activity was assessed as the
arginase activity index (D). Data are expressed as means  SEM. n Z 3.
**P < 0.01, ***P < 0.001, one-way analysis of variance.
Hu et almarker F4/80. For co-culturing experiments, co-culture in-
serts (0.4-mm pores; BD Biosciences) were placed in 6-well
tissue culture plates. BMDMs were added to the tissue cul-
ture wells (1 106 cells per well) and cancer cells (1.5 105)
were added to the inserts. The cells were washed with serum-
free medium and then cultured in serum-free medium for four3386additional days before harvesting the BMDMs for gene
expression analysis or Arg1 activity measurements.
qPCR
For quantitative real-time PCR (qPCR), total RNA was iso-
lated from BMDMs, which were co-cultured with cancer
cells, or from the cancer cells using a NucleoSpin RNA II kit
(Macherey-Nagel, Bethlehem, PA). cDNA was synthesized
using an iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA). qPCR was performed using an Applied
Biosystems StepOnePlus instrument (Life Technologies) and
a one-step program: 95C, 10minutes; 95C, 30 seconds, and
60C, 1 minute for 40 cycles. HPRT1 gene expression was
measured as a normalizer. Results were analyzed by the
relative quantiﬁcation method. All experiments were per-
formed in triplicate with internal duplicate determinations.
Arginase Activity Assay
Arginase activity was measured using a QuantiChrom argi-
nase assay kit (BioAssay Systems, Hayward, CA). BMDMs
that had been co-cultured with breast cancer cells were
washed with 20 mmol/L sodium phospate, 150 mmol/L
NaCl, pH 7.4. Cell extracts were prepared in 10 mmol/L
TriseHCl, pH 7.4, 0.4% Triton X-100, 1 mmol/L pepstatin A,
and 1 mmol/L leupeptin. Cell extracts were incubated withajp.amjpathol.org - The American Journal of Pathology
Figure 3 Urokinase receptor (uPAR) gene silencing in mouse pancreatic
adenocarcinoma PanO2 and glioblastoma (GBM) cells decreases Arg1 expression
in co-cultured bonemarrow-derivedmacrophages (BMDMs).A: Immunoblotting
was performed to detect mouse uPAR and tubulin in PanO2 cells transfected
with a control lentiviral vector (shCon) or with a lentiviral vector encoding
shRNA against uPAR (shuPAR). B: BMDM Arg1 mRNA was analyzed by qPCR after
co-culturing with PanO2 cells that were transduced with shCon or shuPAR. C:
ESC1 and ESC2 GBM cells were transfected with non-targeting control (NTC) or
uPAR-speciﬁc siRNA (siuPAR), and uPAR mRNA levels were determined by qPCR,
standardized against levels present in cells treated with NTC siRNA. D: uPAR
protein expression was determined by immunoblot analysis in cells transfected
with NTC or uPAR-speciﬁc siRNA. E: ESC1 and ESC2 GBM cells were transfected
with NTC or uPAR-speciﬁc siRNA.mRNA levels of BMDMArg1were determined by
qPCR after co-culturing with ESC cells, standardized against levels present in
cells co-cultured with ESC cells transfected with NTC siRNA. Data are expressed
as means  SEM. nZ 3. *P < 0.05, Student’s t-test; ***P < 0.001, one-way
analysis of variance.
Cancer Cell Conditioning of MacrophagesL-arginine for 2 hours, and then urea detection reagent was
added for 2 hours. The absorbance (OD) at 520 nm was
measured. As a control, we also measured the absorbance of
1 mmol of urea. Arginase activity was calculated as follows:
arginase activity index (mmol urea/1  106 cells) Z
(ODsample  ODblank)/(ODstandard  ODwater)  1 mmol 
dilution factor.
Immunoblot Analysis
Cell extracts were prepared in radioimmunoprecipitation
assay buffer containing complete protease inhibitor cocktail.
Protein concentrations were determined by bicinchoninic
acid assay (Sigma-Aldrich). Equal amounts of cell extract
were resolved by SDS-PAGE, electrotransferred to poly-
vinylidene diﬂuoride membranes, and probed to detect the
protein of interest and tubulin as a loading control.
TGF-b ELISA
Breast cancer cells were plated in 60-mm dishes (1  106
cells per plate) for 24 hours and then washed extensively.
The cells were incubated in serum-free medium for an
additional 24 hours. Conditioned medium was harvested.
TGF-b released from cells was measured using enzyme-
linked immunosorbent assay (TGF-b Quantikine ELISA;
R&D Systems). This assay is selective for TGF-b1.
Results
uPAR Expression in Breast Cancer Cells Induces Arg1 in
Co-Cultured Macrophages
MCF-7 cells are estrogen receptor-aeexpressing breast
cancer cells that express low levels of uPAR and undetectable
levels of uPA.30 MDA-MB 468 breast cancer cells express
higher levels of uPAR and also express uPA, allowing
autocrine uPAR signaling.36,38 We overexpressed uPAR in
both cell types to generate stable cell lines, as described
previously.32,33,38 Control cells were transfected with EV.
Cell-surface uPAR expression was compared by ﬂow
cytometry. In control EV-transfected MCF-7 cells, uPAR
expression was insufﬁcient for detection by ﬂow cytometry
(Figure 1A). uPARwas readily detected in control MDA-MB
468 cells. A marked increased in cell-surface uPAR was
observed when MCF-7 or MDA-MB 468 cells were trans-
fected to overexpress uPAR.
To investigate whether uPAR expression in breast cancer
cells promotes conditioning of TAMs, an in vitro co-culture
model system was established. Arg1 mRNA expression was
measured as a biomarker of the M2-polarized macrophage
phenotype in BMDMs that were co-cultured with cancer cells.
Arg1 mRNA was increased in BMDMs co-cultured with
MDA-MB 468 cells, compared withMCF-7 cells (Figure 1B).
uPAR overexpression inMDA-MB468 cells further increased
Arg1 mRNA expression (P < 0.001). Although uPAR over-The American Journal of Pathology - ajp.amjpathol.org 3387
Figure 4 Urokinase receptor (uPAR) induces transforming growth factor b
(TGF-b) expression in MDA-MB breast cancer 468 cells. A: Immunoblot analysis
to detect TGF-b and tubulin was performed on cell extracts from empty vector-
transfected control (EV) and uPAR-overexpressing MCF7 and MDA-MB 468 cells.
B: Conditioned medium from control MDA-MB 468 cells (468/EV) and uPAR-
overexpressing MDA-MB 468 cells (468/uPAR) was subjected to enzyme-
linked immunosorbent assay (ELISA) to detect TGF-b. C: Control MDA-MB 468
cells (EV) and uPAR-overexpressing MDA-MB 468 cells (uPAR) were transfected
with uPA-speciﬁc siRNA (40 nmol/L) or NTC siRNA pool (40 nmol/L). After 24
hours, the cells were cultured in serum-free medium for an additional 24 hours.
mRNA levels were determined by qPCR for urokinase-type plasminogen activator
(uPA) and TGF-b, standardized against levels present in control EV cells
transfected with control siRNA. D: Immunoblot analysis to detect TGF-b and
tubulin was performed on cell extracts from control and uPAR-overexpressing
MDA-MB 468 cells that were transfected with uPA-speciﬁc or NTC siRNA. Data
are expressed as means  SEM. nZ 3. **P < 0.01, Student’s t-test.
Hu et alexpression in MCF-7 cells was associated with a trend toward
increased Arg1 mRNA in co-cultured BMDMs, the difference
was not statistically signiﬁcant.
To conﬁrm the results of the qPCR experiments, we
examined arginase activity using a spectrophotometric
assay.43 A signiﬁcant increase in arginase activity was detec-
ted in BMDMs that were co-cultured with uPAR-
overexpressing MDA-MB 468 breast cancer cells compared
with control, EV-transfected MDA-MB 468 cells (P < 0.05)
(Figure 1C). The increase in arginase activity was lower in
magnitude than the increase in Arg1 mRNA. This may be
explained by the fact that the arginase activity assay detects
two separate arginase isozymes and is affected by interfering
compounds such as ornithine and urea.43
Because the BMDMs were isolated from mice, we per-
formed co-culturing experiments withmouse breast cancer cell
lines. 4T1 cells are highly metastatic breast cancer cells iso-
lated from a spontaneously developed tumor in BALB/c mice.
4T1 cells are known to express high levels of uPA and
uPAR.44,45 168FARN cells also were isolated from a BALB/c
mammary tumor. These cells are tumorigenic, but rarely
metastasize. We conﬁrmed that 4T1 cells express uPAR by
ﬂow cytometry (Figure 2A). The level of cell-surface uPAR in
4T1 cells was approximately fourfold higher than in
168FARN cells. To derive stable cell lines in which uPAR
expression is silenced, 4T1 cells were transduced with the
lentiviral vector pLKO-shmuPAR, which encodes uPAR-
speciﬁc shRNA. Flow cytometry indicated that gene
silencing decreased cell-surface uPAR in 4T1 cells by >80%
(Figure 2B).
In co-culturing experiments, 4T1 cells induced Arg1
expression in BMDMs more effectively than did 168FARN
cells, consistent with our results showing higher uPAR
expression in 4T1 cells (Figure 2C). uPAR gene silencing
in 4T1 cells signiﬁcantly decreased the ability of these
cells to induce Arg1 expression (P < 0.005). These results
were conﬁrmed by measuring BMDM arginase activity
(Figure 2D).
uPAR Controls the Ability of Diverse Cancer Cells to
Condition Macrophages
PanO2 mouse pancreatic adenocarcinoma cells express sub-
stantial levels of uPAR, as determined by immunoblot analysis
(Figure 3A). uPAR gene silencing with pLKO-shmuPAR
essentially blocked expression of uPAR at the protein level in
these cells. Control uPAR-expressing PanO2 cells were sub-
stantially more effective at inducing Arg1 mRNA expression in
BMDMs, compared with cells in which uPAR was silenced
(Figure 3B).
We also studied ESC1 and ESC2 GBM cells. These cells
are derived from different tumors formed by U373MG
GBM cells in mice.39,41 When initially inoculated, the
U373MG cells expressed a constitutively active form of the
EGF receptor; however, expression of this receptor was
blocked in vivo after the tumors were established forcing the3388 ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Urokinase receptor (uPAR) induces transforming growth factor-
beta (TGF-b) expression in metastatic breast cancer 4T1 cells. A: mRNA levels
of TGF-b were determined by qPCR, standardized against levels present in
168FARN mouse mammary cancer cells. B: Immunoblot analysis to detect TGF-
b and tubulin was performed on cell extracts from 168FARN, control 4T1, and
4T1 cells in which uPAR was silenced (4T1-shRNA). C: ELISA to detect TGF-b
was performed on conditioned medium from 168FARN, control 4T1, and 4T1
cells in which uPAR was silenced. Data are expressed as means SEM. nZ 3.
*P < 0.05, one-way analysis of variance.
Cancer Cell Conditioning of Macrophagestumors into a state of dormancy.41 ESC cell lines were
prepared from tumors that regained the capacity to grow
in vivo and are known to express high levels of uPA and
uPAR.39 For the studies reported here, uPAR was silenced
in ESC1 and ESC2 cells using siRNA. uPAR gene silencing
was highly effective at the mRNA level, as determined by
qPCR (Figure 3C), and at the protein level, as determined by
immunoblot analysis (Figure 3D). uPAR gene silencing in
ESC1 and ESC2 cells signiﬁcantly decreased the ability of
these cells to induce Arg1 mRNA expression in co-cultured
BMDMs (Figure 3E).
uPAR Induces Expression of TGF-b in Cancer Cells
TGF-b is well recognized as an important growth factor
released by cancer cells, that expresses immunosuppressive
activities and that conditions TAMs so that they express M2-
polarized phenotypic properties.46e50 We examined TGF-b in
cell extracts from the control and uPAR-overexpressingMCF7
and MDA-MB 468 cells described previously (Figure 1A).
TGF-b was readily detected in extracts of MDA-MB 468 cells
only after uPAR overexpression (Figure 4A). uPAR over-
expression also increased the level of TGF-b detected in
serum-free medium conditioned by MDA-MB 468 cells, as
determined by ELISA selective for TGF-b1 (Figure 4B).
We hypothesized that activation of uPAR signaling sec-
ondary to uPAR overexpression increases expression of TGF-b
in MDA-MB 468 cells. To test this hypothesis, we silenced
uPA in control and uPAR-overexpressingMDA-MB 468 cells,
precluding the possibility for autocrine uPA-initiated uPAR
cell signaling. In cells transfected with NTC siRNA, uPA
mRNA was slightly increased by uPAR overexpression;
TGF-b mRNA was increased approximately 10-fold, consis-
tent with the demonstrated increases in TGF-b protein
(Figure 4C). uPA gene silencing in uPAR-overexpressing
MDA-MB 468 cells was greater than 80% effective, as deter-
mined by qPCR, and was accompanied by a 90% decrease in
TGF-b mRNA expression. We conﬁrmed that uPA gene
silencing inhibits TGF-b expression in uPAR-overexpressing
MDA-MB 468 cells by performing immunoblot analysis
(Figure 4D). These results support a model in which uPA-
initiated uPAR signaling induces TGF-b expression.
Next, we examined TGF-b expression in 168FARN cells,
in wild-type 4T1 cells, and in 4T1 cells in which uPAR
was silenced (Figure 2B). The level of TGF-b mRNA was
approximately twofold higher in 4T1 cells, compared with
168FARN cells (Figure 5A). This difference was conﬁrmed
at the protein level by immunoblot analysis (Figure 5B) and
ELISA (Figure 5C). uPAR gene silencing in 4T1 cells
signiﬁcantly decreased TGF-b protein production and
secretion into the medium (P < 0.05).
IL-4 Is Regulated Downstream of ERK1/2 in GBM Cells
Next, we examined the effects of uPAR gene silencing on
TGF-b expression in GBM cells. Analysis of cell extractsThe American Journal of Pathology - ajp.amjpathol.orgdemonstrated a decrease in TGF-b protein in ESC1 and
ESC2 cells in which uPAR was silenced (Figure 6A). The
decrease in TGF-b protein was conﬁrmed at the mRNA level
in ESC2 cells (Figure 6B). Interestingly, uPAR gene
silencing did not cause a signiﬁcant decrease in TGF-b
mRNA in ESC1 cells. We therefore decided to analyze IL-43389
Figure 6 Urokinase receptor (uPAR) regulates transforming growth
factor-beta (TGF-b) and IL-4 expression in glioblastoma (GBM) cells. A: Cell
extracts from ESC1 and ESC2 cells that were transfected with uPAR-speciﬁc
(þ) or NTC siRNA () were subjected to immunoblot analysis to detect
TGF-b and b-actin. B and C: ESC1 and ESC2 cells were transfected with
uPAR-speciﬁc siRNA (white bars) or NTC siRNA (black bars). After 24 hours,
the cells were cultured in serum-free medium for an additional 24 hours.
mRNA levels of TGF-b (B) and IL-4 (C) were determined by qPCR, stan-
dardized against levels present in ESC1 cells transfected with NTC siRNA.
Data are expressed as means  SEM. n Z 3. *P < 0.05, Student’s t-test.
Figure 7 IL-4 is regulated downstream of ERK1/2 in ESC cells. A:
Immunoblot analysis to detect detected phosphorylated (p-) and total
ERK1/2 on cell extracts from ESC1 and ESC2 cells transfected with uPAR-
speciﬁc (þ) or NTC siRNA (). B: ESC1 and ESC2 cells were treated with
PD98059 (50 mmol/L) or with vehicle in serum-free medium for 30 minutes.
p-ERK1/2 and total ERK1/2 were determined by immunoblot analysis. C and
D: ESC1 and ESC2 cells were treated with PD98059 (50 mmol/L) (white bars)
or vehicle (black bars) in serum-free medium for 4 hours. mRNA levels of
IL-4 (D) and TGF-b (E) were determined by quantitative real-time PCR,
standardized against levels present in vehicle-treated cells. Data are
expressed as means  SEM. n Z 3. *P < 0.05, Student’s t-test.
Hu et allevels in control and uPAR gene-silenced ESC1 and ESC2
cells. uPAR gene silencing induced a signiﬁcant decrease
in IL-4 mRNA expression in ESC1 cells (P < 0.05)
(Figure 6C). In ESC2 cells, IL-4 mRNA expression trended
downward, but the decrease was not signiﬁcant. These results
suggest that uPAR expression in cancer cells may affect
expression of different mediators that have the potential to
condition macrophages.
uPA binding to uPAR activates a network of inter-
connected signaling pathways,29 providing many mecha-
nisms by which expression of factors such as TGF-b and IL-4
may be regulated. In ESC1 and ESC2 cells, uPAR is a sig-
niﬁcant regulator of ERK1/2 activation.39 ERK1/2 is also
activated downstream of uPAR in other cancer cells, including
MCF-7 and MDA-MB 468 breast cancer cells.30,32 When3390uPAR was silenced in ESC1 and ESC2 cells, phosphoryla-
tion of ERK1/2 was decreased (Figure 7A). We therefore
examined whether inhibiting ERK1/2 activation blocks
expression of TGF-b or IL-4 in ESC1 and ESC2 cells. In both
cell lines, PD98059 (50 mmol/L) almost entirely blocked
phosphorylation of ERK1/2 (Figure 7B). PD98059 also
signiﬁcantly decreased IL-4 mRNA expression (Figure 7C).
TGF-bmRNA expression was unaffected (Figure 7D). These
results suggest that, in cancer cells, expression of factors that
condition TAMs may be regulated by uPAR through itsajp.amjpathol.org - The American Journal of Pathology
Cancer Cell Conditioning of Macrophageseffects on activation of ERK1/2 or other signaling factors
controlled in concert.Discussion
Mechanisms by which uPAR promotes cancer progression
remain incompletely understood. Cell-signaling pathways
activated downstream of uPAR promote cancer cell survival,
proliferation, migration, invasion, and epithelialemesenchymal
transition.29e37 uPAR also induces stem cellelike properties in
cancer cells.38 The role of cancer-cell uPAR in the conditioning
of inﬂammatory cells in the tumor microenvironment had not
been explored previously. In the present study, we investigated
whether uPAR expression by cancer cells regulates the ability
of these cells to control the phenotype ofmacrophages. Because
we performed co-culturing experiments with cell-culture in-
serts, there was no direct contact between the cancer cells and
the BMDMs and therefore only soluble mediators had an op-
portunity to affect the results.
In these studies with human and mouse breast cancer cells,
we showed that uPAR expression correlates with the ability of
these cells to secrete mediators that condition BMDMs so that
the BMDMs express the M2 macrophage biomarker Arg1.
Macrophage Arg1 may promote cancer progression by sup-
pressing production of cytotoxic levels of nitric oxide.22,23 Our
observation regarding uPAR and the ability of cancer cells to
induce Arg1 expression in macrophages was reproduced
when we examined pancreatic adenocarcinoma cells and
GBM cells. Thus, the ability of cancer-cell uPAR to promote
tumor-permissive conditioning of macrophages appears to be
conserved across diverse neoplasms.
We propose that uPAR-activated cell signaling in cancer
cells increases expression of soluble mediators that condi-
tion TAMs in the tumor microenvironment to allow cancer
progression. The complete spectrum of soluble mediators
that may be induced by uPAR remains to be determined. In
MDA-MB 468, 4T1, and ESC GBM cells, uPAR increased
expression of TGF-b, a known immunosuppressant in the
tumor microenvironment.46 TGF-b targets multiple immune
system cell types and, in macrophages, induces M2-
polarized characteristics.46e50 In addition to regulating
TGF-b expression, as demonstrated here, uPAR also may be
involved in TGF-b activation. Plasminogen, which is acti-
vated by uPAR-associated uPA to form plasmin, converts
biologically inactive, latent TGF-b into the active growth
factor.51 Active TGF-b increases expression not only of
uPA, but also of other proteins that may participate in
uPAR-initiated cell signaling, such as plasminogen activator
inhibitor-1.52,53 These synergistic pathways may combine to
form positive feedback loops, which further activate uPAR
signaling in cancer cells and further enable cancer cells to
condition local TAMs.
To determine the role of uPAR-initiated cell signaling
in regulation of TGF-b expression, we silenced uPA in
uPAR-overexpressing MDA-MB 468 cells. Although uPARThe American Journal of Pathology - ajp.amjpathol.orgsignals independently of uPA when expressed at high
levels,32 uPA binding to uPAR substantially increases the
amplitude of uPAR signaling and also triggers cell signaling
when the uPAR copy number is low.30 uPA gene silencing
completely blocked the increase in TGF-b expression
associated with uPAR overexpression. Next, we studied
ESC1 and ESC2 GBM cells. We previously demonstrated
that uPAR is a major regulator of ERK1/2 activation in
these cells.39 uPAR gene silencing decreased phosphory-
lated ERK1/2 in both ESC1 and ESC2 cells. When ERK1/2
activation was pharmacologically blocked with PD98059,
IL-4 expression was signiﬁcantly decreased in the ESC
cells. IL-4 expression also was signiﬁcantly decreased by
uPAR gene silencing in one of the two GBM cell lines
(ESC1). IL-4 is expressed by cancer cells and involved in
M2 polarization of macrophages.18e21 Importantly, TGF-b
expression was not regulated by PD98059, suggesting that
the effects of uPAR on TGF-b expression are unrelated to
its activity in controlling ERK1/2 activation in these cells.
ESC1 and ESC2 cells were derived from the same
parental cells, which were propagated as tumors in separate
mice.41 Expression of a constitutively active form of the
EGF receptor in the parental cells was silenced in vivo. This
silencing placed pressure on the cancer cells, which subse-
quently entered a state of dormancy. Multiple molecular
changes may occur in cancer cells when they emerge from
dormancy.54 In ESC1 and ESC2 cells, increased expression
of uPA and activation of uPAR signaling were observed.39
The difference in regulation of IL-4 and TGF-b observed
when uPAR was silenced in ESC1 and ESC2 cells probably
reﬂects other molecular changes that allowed re-establishment
of growth in vivo. Nevertheless, uPAR-driven soluble me-
diators controlled macrophage Arg1 similarly in both GBM
cell lines. Taken together, our results suggest that cancer-
permissive conditioning of macrophages may be a general
activity of cancer-cell uPAR, mediated by a set of secreted
immunomodulatory factors in distinct proportions in
different cancer cells.Acknowledgments
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